Clay B Siegall bought $1.2M of Immunome (IMNM)
Executed Jan 31 2025, disclosed Feb 3 2025, 3 days later.
Over the 21 trading sessions from the disclosed entry session (Feb 3 2025), the stock returned -15.7% (delay-adjusted); from the execution session (Jan 31 2025), -15.2%. Derived: entry at the session's open, exit at the close 20 sessions later.
Clay B Siegall (President and CEO) filed 5 Form 4 reports in the trailing twelve months (5 purchases, 0 sales), most often in Immunome, Inc. (IMNM). Across 5 priced purchase filings, the average 21-session return was +28.7% from execution and +24.2% from disclosure (delay-adjusted; derived). The largest single filing was $1000K of IMNM (46,511 sh × $21.50, as filed), executed Dec 18 2025.
Healthcare · Immunome, Inc., a biotechnology company, engages in the discovery, design, development, manufacturing, and commercialization of antibody-dr…
More Healthcare filings→ Insider filings, newest first→ View the original filing at www.sec.gov→25,450 sh × $19.67
Exec Mar 27
Filed Mar 31 · 7:11 AM ET IMNMPURCHASE Immunome, Inc. $100K
4,729 sh × $21.15
Exec Dec 30 2025
Filed Dec 30 2025 · 6:47 PM ET IMNMPURCHASE Immunome, Inc. $149K
7,278 sh × $20.48
Exec Dec 19 2025
Filed Dec 22 2025 · 7:38 AM ET IMNMPURCHASE Immunome, Inc. $1000K
46,511 sh × $21.50
Exec Dec 18 2025
Filed Dec 18 2025 · 5:03 PM ET IMNMPURCHASE Immunome, Inc. $999K
137,100 sh × $7.29
Exec Mar 26 2025
Filed Mar 26 2025 · 5:30 PM ET IMNMPURCHASE Immunome, Inc. $962K
100,000 sh across 2 lots
Exec Nov 21 2024
Filed Nov 25 2024 · 5:30 PM ET